To address this challenge, researchers have developed the first nanobody-based inhibitors targeting the Ebola virus. Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50% ...

To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first nanobody-based inhibitors targeting the Ebola ...

This binding prevents the virus from utilizing its glycoprotein for attachment and fusion, thereby halting ... These findings support the potential of nanobody technology in addressing viral ...

To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first nanobody-based inhibitors targeting the Ebola ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab ... and pathologic bone formation and joint fusion, severely limiting spinal mobility.

MoonLake Immunotherapeutics AG New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 ...